BIO CEO & Investor Conference

Feb. 9, 2009-Feb. 10, 2009
Waldorf-Astoria
New York, NY
ceo.bio.org

Description:

Ben Bonifant, head of our Business Development Practice will moderate a panel discussion on upfront payments including participation from Targacept, Exelixis, Celgene, Merck, and Regulus Therapeutics.

Members of the Campbell Alliance executive management team will be attending this event to coordinate meetings with pharma and biotech CEOs.

Abstract:

Biotech Licensing: Being Upfront about Upfront Payments

Moderator:
 
Ben Bonifant, Vice President, Business Development Practice, Campbell Alliance
 

Panelists:

  • J. Donals deBethizy, Ph.D., President and CEO, Targacept
  • Fran Heller, Executive Vice President, Business Development, Exelixis
  • Perry Karsen, Head of Worldwide Business Development, Celgene
  • Barbara Yanni, Head of Business Development, Merck
  • Kleanthis G. Xanthopoulos, Ph.D., President and CEO, Regulus Therapeutics
Licensing deals allow big companies to tap into the entrepreneurial spirit of their smaller counterparts and to fill in their pipelines without having to do the upfront work. Likewise, these sought-after alliances give the small companies the non-dilutive capital and scientific validation that they crave. This panel will focus on recent deals that were characterized by especially impressive upfront payments. Business development professionals from some of the companies involved in the past year’s licensing deals will discuss how they successfully forged these deals, how they and their licensing partner calculated the deal terms and upfront payments that they did, and whether their deals serve as realistic benchmarks for future licensing around the industry.

View Entire Event Calendar

Don't Miss